GlaxoSmithKline PLC ADR (GSK)

Official site

HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

$51.10

+0.35 (+0.69%)

Market Cap: $101.68B

Last updated: Oct 27, 2026 at 10:40 AM ET

Earnings

Performance (10Y)

Beat Rate

92%(36/39)

Avg Surprise

+16.03%

Streak

10 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$1.33

Range$1.31 - $1.34

2 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$1.41-6.1%

60d ago$1.34-1.3%

30d ago$1.35-1.8%

7d ago$1.35-1.8%

Current$1.33

Revenue Consensus

$8.8B

Range$8.7B - $8.9B

7 analysts

Period ending Dec 31, 2026

EPS Consensus$0.97

Range$0.89 - $1.13

5 analysts

Revenue Consensus

$9.2B

Range$8.8B - $9.6B

21 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$0.97	$0.89 - $1.13	-	-	5	-	-
Sep 30, 2026Sep 26EST	-	$1.33	$1.31 - $1.34	-	-	2	0 2 30d	-
Jun 30, 2026Jun 26 Reported Jul 28, 2026Reported Jul 28	$1.36	$1.27	$1.24 - $1.27	+7.09%	Beat	2	1 1 30d	+9.7%
Mar 31, 2026Mar 26 Reported Apr 29, 2026Reported Apr 29	$1.26	$1.16	$1.15 - $1.18	+8.62%	Beat	2	2 0 30d	+5.0%
Dec 31, 2025Dec 25 Reported Feb 4, 2026Reported Feb 4	$0.70	$0.62	$0.60 - $0.65	+12.90%	Beat	2	2 0 30d	+20.7%
Sep 30, 2025Sep 25 Reported Oct 29, 2025Reported Oct 29	$1.46	$1.26	$1.26 - $1.27	+15.87%	Beat	2	2 0 30d	+13.2%
Jun 30, 2025Jun 25 Reported Jul 30, 2025Reported Jul 30	$1.24	$1.11	$1.10 - $1.12	+11.71%	Beat	2	0 2 30d	+11.7%
Mar 31, 2025Mar 25 Reported Apr 30, 2025Reported Apr 30	$1.20	$1.04	$1.01 - $1.07	+15.38%	Beat	2	1 1 30d	+11.1%
Dec 31, 2024Dec 24 Reported Feb 5, 2025Reported Feb 5	$0.58	$0.49	$0.47 - $0.50	+18.37%	Beat	2	2 0 30d	-20.5%
Sep 30, 2024Sep 24 Reported Oct 30, 2024Reported Oct 30	$1.29	$1.16	$1.15 - $1.32	+11.21%	Beat	2	No revisions (30d)	+5.7%
Jun 30, 2024Jun 24 Reported Jul 31, 2024Reported Jul 31	$1.11	$0.98	$0.98 - $0.99	+13.27%	Beat	2	1 0 30d	+11.0%
Mar 31, 2024Mar 24 Reported May 1, 2024Reported May 1	$1.08	$0.94	$0.94 - $0.94	+14.89%	Beat	1	No revisions (30d)	+17.4%
Dec 31, 2023Dec 23 Reported Jan 31, 2024Reported Jan 31	$0.73	$0.77	$0.77 - $0.77	-5.19%	Miss	1	1 0 30d	+14.1%
Sep 30, 2023Sep 23 Reported Nov 1, 2023Reported Nov 1	$1.22	$1.14	$1.14 - $1.14	+7.02%	Beat	1	0 1 30d	+14.0%
Jun 30, 2023Jun 23 Reported Jul 26, 2023Reported Jul 26	$1.00	$0.87	$0.87 - $0.87	+14.94%	Beat	1	1 0 30d	+14.9%
Mar 31, 2023Mar 23 Reported Apr 26, 2023Reported Apr 26	$0.92	$0.82	$0.82 - $0.82	+12.20%	Beat	1	0 1 30d	-10.7%
Dec 31, 2022Dec 22 Reported Feb 1, 2023Reported Feb 1	$0.64	$0.55	$0.55 - $0.55	+16.36%	Beat	1	0 1 30d	-26.4%
Sep 30, 2022Sep 22 Reported Nov 2, 2022Reported Nov 2	$1.07	$0.89	$0.89 - $0.89	+20.22%	Beat	1	No revisions (30d)	-15.1%
Jun 30, 2022Jun 22 Reported Jul 27, 2022Reported Jul 27	$0.87	$0.73	$0.73 - $0.73	+19.18%	Beat	1	No revisions (30d)	-11.2%
Mar 31, 2022Mar 22 Reported Apr 27, 2022Reported Apr 27	$1.03	$0.96	$0.96 - $0.96	+7.29%	Beat	1	0 1 30d	+28.7%
Dec 31, 2021Dec 21 Reported Feb 9, 2022Reported Feb 9	$0.87	$0.81	$0.81 - $0.81	+7.41%	Beat	1	1 0 30d	+8.7%
Sep 30, 2021Sep 21 Reported Oct 27, 2021Reported Oct 27	$1.26	$1.02	$1.02 - $1.02	+23.53%	Beat	1	No revisions (30d)	+8.6%
Jun 30, 2021Jun 21 Reported Jul 28, 2021Reported Jul 28	$0.98	$0.41	$0.41 - $0.41	+139.02%	Beat	1	No revisions (30d)	+58.1%
Mar 31, 2021Mar 21 Reported Apr 28, 2021Reported Apr 28	$0.80	$0.60	$0.60 - $0.60	+33.33%	Beat	1	No revisions (30d)	-31.0%
Dec 31, 2020Dec 20 Reported Feb 3, 2021Reported Feb 3	$0.80	$0.60	$0.60 - $0.60	+33.33%	Beat	1	No revisions (30d)	-1.2%
Sep 30, 2020Sep 20 Reported Oct 28, 2020Reported Oct 28	$1.16	$1.07	$1.07 - $1.07	+8.41%	Beat	1	No revisions (30d)	-6.5%
Jun 30, 2020Jun 20 Reported Jul 29, 2020Reported Jul 29	$0.62	$0.71	$0.71 - $0.71	-12.68%	Miss	1	1 0 30d	-34.7%
Mar 31, 2020Mar 20 Reported Apr 29, 2020Reported Apr 29	$1.16	$0.78	$0.78 - $0.78	+48.72%	Beat	1	No revisions (30d)	+18.4%
Dec 31, 2019Dec 19 Reported Feb 5, 2020Reported Feb 5	$0.81	$0.76	$0.76 - $0.76	+6.58%	Beat	1	No revisions (30d)	-19.8%
Sep 30, 2019Sep 19 Reported Oct 30, 2019Reported Oct 30	$1.24	$1.00	$1.00 - $1.00	+24.00%	Beat	1	1 0 30d	+9.7%
Jun 30, 2019Jun 19 Reported Jul 24, 2019Reported Jul 24	$0.95	$0.78	$0.78 - $0.78	+21.79%	Beat	1	No revisions (30d)	+3.3%
Mar 31, 2019Mar 19 Reported May 1, 2019Reported May 1	$0.98	$0.80	$0.80 - $0.80	+22.50%	Beat	1	No revisions (30d)	+14.0%
Dec 31, 2018Dec 18 Reported Feb 6, 2019Reported Feb 6	$1.01	$0.88	$0.88 - $0.88	+14.77%	Beat	1	No revisions (30d)	+7.4%
Sep 30, 2018Sep 18 Reported Oct 31, 2018Reported Oct 31	$1.13	$1.07	$1.07 - $1.07	+5.61%	Beat	1	No revisions (30d)	+4.6%
Jun 30, 2018Jun 18 Reported Jul 25, 2018Reported Jul 25	$0.92	$0.97	$0.97 - $0.97	-5.15%	Miss	1	No revisions (30d)	+3.4%
Mar 31, 2018Mar 18 Reported Apr 25, 2018Reported Apr 25	$0.86	$0.86	$0.86 - $0.86	+0.00%	Beat	2	No revisions (30d)	+7.5%
Dec 31, 2017Dec 17 Reported Feb 7, 2018Reported Feb 7	$0.94	$0.84	$0.80 - $0.87	+11.90%	Beat	2	No revisions (30d)	+14.6%
Sep 30, 2017Sep 17 Reported Oct 25, 2017Reported Oct 25	$1.08	$1.02	$1.02 - $1.02	+5.88%	Beat	1	No revisions (30d)	-
Jun 30, 2017Jun 17 Reported Jul 26, 2017Reported Jul 26	$0.89	$0.84	$0.83 - $0.84	+5.95%	Beat	2	No revisions (30d)	-
Mar 31, 2017Mar 17 Reported Apr 26, 2017Reported Apr 26	$0.80	$0.77	-	+3.90%	Beat	-	-	-
Dec 31, 2016Dec 16 Reported Feb 8, 2017Reported Feb 8	$0.82	$0.78	-	+5.13%	Beat	-	-	-

Dividends

Dividend Metrics

Forward Yield3.53%

Forward Annual Dividend$1.81

Payout Ratio31.69%

FrequencyQuarterly

Pay MonthsJan, Apr, Jul, Oct

Growth

3Y CAGR-4.10%

5Y CAGR-8.83%

GSK dividend history and ex-dividend dates Run GSK in the free DRIP calculator

Key Metrics

Valuation
P/E Ratio	10.69	EV/EBITDA	10.52x
Price/FCF	11.12x	FCF Yield	8.99%
Profitability
Profit Margin	14.50%	Operating Margin	30.90%
ROE	33.40%	ROIC	16.59%
Financial Health
Debt/Equity	1.03x	Interest Coverage	9.56x
Current Ratio	0.82x	Quick Ratio	0.52x
Trading Statistics
Beta	0.28	Avg Volume	5.71M
52-Week High	$60.11	52-Week Low	$41.42

Technical Indicators Dashboard

Moving Averages

SMA 10$49.58

SMA 20$48.38

SMA 50$49.60

SMA 200$51.86

EMA 10$49.85

EMA 20$49.28

EMA 50$49.52

EMA 200$49.77

MACD

Line: 0.42Signal: -0.08Hist: 0.50

ADX

ADX: 22.2+DI: 34.9-DI: 16.3

Aroon & PSAR

Aroon Up92.0

Aroon Down52.0

PSAR$48.00

Bollinger Bands

Upper Band$51.88

Lower Band$44.89

%B Position1444%(Upper)

Band Width0.89

RSI (14-Day)

Neutral

61.4

Momentum Oscillators

Stoch %K92.6

Stoch %D89.6

Williams %R-6.0

ROC (10d)8.9%

Momentum4.18

CCI (20d)114.5

MFI (14d)69.6

Volatility Measures

ATR (14d)$1.01(2.0%)

StdDev (20d)1.75

Hist Vol25.4%(Moderate)

Volume Flow

VWAP$51.06

OBV63.7M

AD Line-2.7B

CMF (20d)-0.076

Volume Metrics

Avg Vol (20d)5.8M

Vol Ratio0.6x

VWMA (20d)$48.06

Pivot Points

R3$51.65

R2$51.28

R1$51.02

Pivot Point$50.65

S1$50.39

S2$50.02

S3$49.76

Advanced Oscillators

TSI9.29

Ultimate Osc58.7

KST-5.93

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$8.41B	$7.63B	$8.62B	$8.55B	$7.99B	$7.52B	$8.12B	$8.01B	$7.88B	$7.36B	$8.05B	$8.15B
Cost of Revenue	$2.27B	$1.88B	$2.66B	$2.26B	$2.17B	$1.94B	$2.56B	$2.40B	$2.12B	$1.97B	$2.42B	$2.27B
Gross Profit	$6.14B	$5.75B	$5.96B	$6.29B	$5.82B	$5.58B	$5.56B	$5.62B	$5.76B	$5.39B	$5.63B	$5.88B

Operating Expenses	$5.66B	$3.46B	$4.46B	$3.70B	$3.80B	$3.36B	$4.86B	$5.43B	$4.12B	$3.90B	$5.06B	$3.93B
R&D	$3.47B	$1.69B	$2.35B	$1.69B	$2.02B	$1.46B	$2.03B	$1.46B	$1.48B	$1.43B	$2.05B	$1.57B
SG&A	$2.20B	$2.12B	$2.64B	$2.24B	$2.14B	$2.07B	$2.66B	$3.80B	$2.46B	$2.09B	$2.68B	$2.30B
Operating Income	$481.00M	$2.29B	$1.51B	$2.59B	$2.02B	$2.22B	$696.00M	$189.00M	$1.65B	$1.49B	$573.00M	$1.95B

Interest Income	$58.00M	$22.00M	$150.00M	$26.00M	$136.00M	$54.00M	$28.00M	$32.00M	$24.00M	$32.00M	$38.00M	$158.00M
Interest Expense	$182.00M	$167.00M	$174.00M	$167.00M	$184.00M	$162.00M	$144.00M	$156.00M	$174.00M	$166.00M	$275.41M	$182.00M
Income Before Tax	$354.00M	$2.14B	$950.00M	$2.46B	$1.89B	$2.11B	$563.00M	$64.00M	$1.50B	$1.35B	$379.00M	$1.79B
Income Tax Expense	$-199,000,000	$305.00M	$223.00M	$312.00M	$241.00M	$336.00M	$62.00M	$-1,000,000	$191.00M	$274.00M	$-19,000,000	$257.00M

Net Income	$435.00M	$1.74B	$636.00M	$2.01B	$1.44B	$1.62B	$414.00M	$-58,000,000	$1.17B	$1.05B	$350.00M	$1.46B

EBITDA	$760.81M	$2.77B	$1.91B	$3.36B	$3.23B	$3.09B	$1.12B	$1.17B	$2.31B	$2.07B	$1.16B	$2.55B
EBIT	$536.00M	$2.31B	$1.12B	$2.62B	$2.07B	$2.27B	$707.00M	$220.00M	$1.67B	$1.52B	$534.00M	$1.97B

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about GSK

Government Contracts

Gov Obligations (TTM)

$21.03M

Gov Obligations / Revenue

0.1%

Obligations YoY

-25.4%

Active Awards

New Awards (TTM)

Avg Remaining Term

9.2 mo

Top agency: Department of Health and Human Services at 95.8% of trailing twelve month obligations across 4 agencies

Recent Awards

Award ID	Agency	Obligated	Start	End	Description
75A50325C00019	Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response	$18.20M	Sep 30, 2025	Sep 29, 2027	RELENZA (ZANAMIVIR) ROTADISK, 5MG
19AQMM25F1490	Department of StateDepartment of State	$667575	Sep 9, 2025	Oct 9, 2025	2025 - 2026 FLU VACCINES
75A50126F61020	Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response	$493470	Mar 13, 2026	Oct 29, 2026	TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN
15F06726F0000234	Department of JusticeFederal Bureau of Investigation	$105000	Feb 27, 2026	Dec 31, 2026	GSK VACCINES
W901UZ25FA029	Department of DefenseDepartment of the Army	$32603	Aug 21, 2025	Sep 13, 2025	210 BOXES FLUARIX TRIVALENT, INFLUENZA VACCINE,TRIVALENT (PF),SYRINGE,0.5ML
19PCRD26K1498	Department of StateDepartment of State	$24928	Dec 8, 2025	Jan 2, 2026	MEDICAL SUPPLIES
19PCRD26K1497	Department of StateDepartment of State	$24928	Dec 8, 2025	Jan 2, 2026	MEDICAL SUPPLIES
19PCRD26K1496	Department of StateDepartment of State	$24928	Dec 8, 2025	Jan 2, 2026	MEDICAL SUPPLIES
W912L726FA017	Department of DefenseDepartment of the Army	$15076	Apr 23, 2026	May 23, 2026	HEPATITIS A AND B VACCINES FOR TENNESSEE ARMY NATIONAL GUARD.

Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

News

GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study

An experimental drug called ris-rez, developed by Hansoh Pharmaceutical and GSK for a hard-to-treat bone cancer...

Reuters•Oct 26, 2026 12:12 PM ET10/26/26•Bullish

At $51.21 each, GSK (NYSE: GSK) president acquires 9.324 notional depositary shares.

Maya Martinez-Davis, President of GSK plc, acquired 9.324 notional American Depositary Shares (ADS) for $51.2100 each on October 22...

Stock Titan•Oct 26, 2026 12:10 PM ET10/26/26•Neutral

REG - GSK PLC - Director/PDMR Shareholding

GSK plc announced an initial notification regarding a Director/PDMR Shareholding. Maya Martinez-Davis, President, US...

TradingView•Oct 26, 2026 11:12 AM ET10/26/26•Neutral

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

GSK has released updated positive data from its global phase I BEHOLD-1 trial for mocertatug rezetecan (Mo-Rez), an investigational B7-H4-targeted antibody-drug conjugate (ADC)...

GSK•Oct 24, 2026 3:12 PM ET10/24/26•Bullish

GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Estimates – BCBA:GSK.CI

This article provides an overview of GSK PLC ADR financial actuals and estimates for the BCBA:GSK.CI ticker on the Buenos Aires Stock Exchange. It highlights access to reported financial data and analyst estimates across...

TradingView•Oct 23, 2026 9:41 AM ET10/23/26•Neutral

GSK Valuation and Fair Value

P/E: 10.7x
Forward P/E: 9.8x
EV/EBITDA: 10.5x
P/FCF: 11.1x
PEG: 6.1x
P/B: 4.5x

See GNG's fair value

GSK Profitability: Margins, ROIC and FCF

Gross margin: 72.7%
Operating margin: 30.9%
Net margin: 14.5%
ROIC: 16.6%
ROE: 33.4%
FCF margin: 15.7%
FCF yield: 9.0%

GSK Competitors

Company	Ticker
McKesson Corporation	MCK
HCA Healthcare, Inc.	HCA
Stryker Corporation	SYK
Sanofi ADR	SNY
CVS Health Corp	CVS
Elevance Health Inc	ELV
Medtronic PLC	MDT
Regeneron Pharmaceuticals Inc	REGN

Sector: Healthcare

GSK Analyst Ratings

Consensus: Hold
Analysts: 8
Strong Buy: 1
Buy: 2
Hold: 4
Sell: 1
Strong Sell: 0

GSK Bull Case vs Bear Case

Bull case

GSK earns a 16.6% return on invested capital.
GSK converts 15.7% of revenue into free cash flow.
GSK beat EPS estimates in 100.0% of its last 8 reported quarters.

GSK Earnings: Beat Rate and Next Report

Beat rate: 8 of 8 quarters (100.0%)
Average surprise: 12.6%
EPS estimate (fiscal period ending Sep 30, 2026): $1.33
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 2 down

GSK Dividend

Forward yield: 3.5%
Payout ratio: 31.7%
3Y DPS growth: -4.1%
5Y DPS growth: -8.8%
Pay months: Jan, Apr, Jul, Oct

GSK dividend history

Frequently Asked Questions About GSK

What is GSK's current dividend yield?

GlaxoSmithKline PLC ADR (GSK) has a forward dividend yield of 3.53%.

Does GSK pay dividends?

Yes, GlaxoSmithKline PLC ADR pays dividends with a forward dividend yield of 3.53%.

What is GSK's P/E ratio?

GlaxoSmithKline PLC ADR has a price-to-earnings (P/E) ratio of 10.69.

What is GSK's market cap?

GlaxoSmithKline PLC ADR (GSK) has a market capitalization of $101.68B with a current stock price of $51.10.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In